Key Drivers
- Positive FCF
- High leverage
- Thin margins
AIAI Summary
With the $16.50 take‑private bid turning Select Medical into a transaction‑driven value play, near‑term returns now depend on deal completion (significant litigation/reopening risk) while any upside beyond the bid requires proving outpatient margin recovery and executing capital‑intensive IRF growth under heavy leverage—treat this as a deal bet and size or sit out until transaction clarity.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Positive FCF
- •High leverage
- •Thin margins
SEM generates steady revenue and full‑year free cash flow but faces thin margins, elevated leverage and tight liquidity that constrain upside.
Price Behavior
Key Price Behavior Insights:
- •Above last month SMA
- •Tight resistance band
- •Extreme RSI overbought
SEM is holding above its last month SMA (~$15.79) after a gap from $15.00 to $16.26 and has consolidated near $16.25–$16.27 (resistance) but shows extreme RSI risk of a pullback.
Large gap up from $15.00 to $16.26 on 2026-03-03 driving elevated
Sentiment & News
Key News Insights:
- •Multiple investigations
- •Offer seen low
- •Stock jumped
Select Medical agreed to a $16.50-per-share take-private led by Executive Chairman Robert Ortenzio, sparking multiple shareholder law firm probes over deal fairness even as stock and some analyst targets suggest potential upside.
The legal scrutiny and analyst skepticism could pressure any deal renegotiation or litigation risk, creating short-term uncertainty for Select Medical shares
Similar Companies in Healthcare
Other companies in the same sector with AI ratings